QuickView for YDL143W;jsessionid=AF9A6F4065C670FDF1AB5408FD20ADBE;jsessionid=83E286E74EDD02FF9D8798CF638465E5;jsessionid=D7FFE99F12BF2E4EB7D38EBC69DA554B;jsessionid=36F903B008D559D25B0614918BC4DCE5;jsessionid=465606163BCE8F6E8A7CE02352D7D8E0;jsessionid=5FDBDA002C760DB8F7FDD11DC336F5A1;jsessionid=FA095AEB86317D6EB93794149813C770;jsessionid=52211B7CEF7CB801EB9EAD6FBA400E12;jsessionid=649A099F9EA95BDF20FEDDE71125E1E6;jsessionid=0CE56F72F3173C49E82BD9CD65050630 (gene)

1. Biochemical characterization of mutants in chaperonin proteins CCT4 and CCT5 associated with heredit…
2. Role of CCT4/ErbB signaling in nephroblastoma: Implications for a biomarker of Wilms tumor.
3. Anticarin-β shows a promising anti-osteosarcoma effect by specifically inhibiting CCT4 to impair pro…
4. Transient Kinetic Analysis of ATP Hydrolysis by the CCT/TRiC Chaperonin.
5. CCT4 knockdown enhances the sensitivity of cisplatin by inhibiting glycolysis in human esophageal sq…

There were no clinical trials for YDL143W;jsessionid=AF9A6F4065C670FDF1AB5408FD20ADBE;jsessionid=83E286E74EDD02FF9D8798CF638465E5;jsessionid=D7FFE99F12BF2E4EB7D38EBC69DA554B;jsessionid=36F903B008D559D25B0614918BC4DCE5;jsessionid=465606163BCE8F6E8A7CE02352D7D8E0;jsessionid=5FDBDA002C760DB8F7FDD11DC336F5A1;jsessionid=FA095AEB86317D6EB93794149813C770;jsessionid=52211B7CEF7CB801EB9EAD6FBA400E12;jsessionid=649A099F9EA95BDF20FEDDE71125E1E6;jsessionid=0CE56F72F3173C49E82BD9CD65050630